Cybin Overview
Latest ROE for Cybin: -71.55% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-71.55%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Cybin (CYBN) currently reports a ROE of -71.55%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Cybin's ROE history and peer comparisons.
Cybin's ROE of -71.55% is lower than the Healthcare sector average of 22.76%. That is roughly 414.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Cybin's current -71.55% should be judged against Healthcare norms (sector average: 22.76%) and against CYBN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -71.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Cybin, and consider following CYBN for alerts when major investors trade the stock.
Cybin is classified in the Healthcare sector. On ROE, it currently shows -71.55% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYBN with unrelated industries.
